Breaking News

Financial Report: Amgen

August 7, 2014

Revenues up 11% in the quarter


2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $1.5 billion (+26%)

YTD Revenues: $9.7 billion (+9%)

YTD Earnings: $2.6 billion (-35%)

Comments: Enbrel sales increased 7% to $1.2 billion in the quarter. Kyprolis sales were $78 million (acquired from Onyx Pharmaceuticals acquisision in 4Q13). Prolia sales increased 40% to $264 million. XGEVA sales increased 20% to $299 million, despite generic competition. Combined Neulasta (pegfilgrastim) and NEUPOGEN (filgrastim) sales declined 1% to $1.4 billion in the quarter. R&D expenses in the quarter were up 4% to $979 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks